Artificial Life and Therapeutic Vaccines Against Cancers that Originate in Viruses

  • María Elena Escobar-OspinaEmail author
  • Jonatan Gómez


The construction of artificial life processes that seek to contribute to the development of therapeutic vaccines to treat human cancers, which have their origin in infectious processes caused by viruses, requires research on three fronts. On the one hand, to know the life cycle of the virus under study, as well as to recognize the mechanisms and strategies that it can implement to attack its host and proceed to infect it. On the other hand, to acknowledge the components, mechanisms and strategies that the immune system develops to identify the presence of a stranger and prepare to repel it, in response to the kind of attack that poses. And finally, to design the strategies, that exogenously, allow activating the host’s immune system so that it prepares answers with objectives aimed at counteracting the injuries caused by the virus that attacks it. This chapter describes in general, the methods that through a process of artificial life, allow to simulate the interactions that arise between human immune system, pathogen (viruses as etiological agents of cancer), and therapeutic vaccines to treat lesions that originates in the activity of this type of pathogen.


Artificial life Artificial immune system Cancer Virus Simulation model Therapeutic vaccine Toll-like receptors Cytokines 


  1. 1.
    Globocan. Estimated cancer incidence, mortality and prevalence worldwide in 2012. France. 2012. Accessed 24 Mar 2018.
  2. 2.
    International Agency for Research on Cancer (IARC). Cancers attributable to infections. France. 2018. Accessed 24 Mar 2018.
  3. 3.
    Katz JS. What is a complex innovation system? In SPRU Working paper Series. Ciarli T, Rotolo D, editors. University of Sussex. Montreal, Quebec, Canada. 2015, Jul. ISSN: 2057-6668.Google Scholar
  4. 4.
    Meyers RA, editor. Encyclopedia of complexity and systems science. SpringerScience+BusinessMedia, LLC., New York; 2009; p. 92–271. ISBN: 978-0-387-30440-3.Google Scholar
  5. 5.
    Merelli E, Rucco M, Sloot P, Tesei L. Topological characterization of complex systems: using persistent entropy. Entropy. 2015;17(10):6872–92. Scholar
  6. 6.
    Sayama H, editor. Introduction to the modeling and analysis of complex systems. Binghamton University, SUNY. 2015. ISBN 978-1-942341-08-6.Google Scholar
  7. 7.
    Mitleton-Kelly E, editor. Complex systems and evolutionary perspectives on organisations: the applications of complexity theory to organisations. Advances series in management. Oxford, UK: Elsevier Science Ltd; 2003. ISBN 9780080439570.Google Scholar
  8. 8.
    Mitchell M, Newman M. Complex systems theory and evolution. In: Pagel M, editor. Encyclopedia of evolution. New York: Oxford University Press; 2002. ISBN: 978-0-195-12200-8.Google Scholar
  9. 9.
    Martínez-García M, Hernández-Lemus E. Health systems as complex systems. Am J Oper Res. 2013;3(1A):113–26. Scholar
  10. 10.
    Ellis B, Herbert SI. Complex adaptive systems (CAS): an overview of key elements, characteristics and application to management theory. Inform Prim Care. 2011;19(1):33–7. Scholar
  11. 11.
    Pathak SD, Day JM, Nair A, Sawaya WJ, Kristal MM. Complexity and adaptivity in supply networks: building supply network theory using a complex adaptive systems perspective. Decis Sci. 2007;38(4):547–80. Scholar
  12. 12.
    Alcocer-Cuarón C, Rivera AL, Castaño VM. Hierarchical structure of biological systems. A bioengineering approach. Bioengineered. 2014;5(2):73–9. Scholar
  13. 13.
    Qian H. Stochastic physics, complex systems and biology. Quantitative Biol. 2013;1(1):50–3. Scholar
  14. 14.
    Voit EO, editor. A first course in systems biology. Chapter 1: biological systems. New York: Garland Science; 2012; 496 p . ISBN: 9789-0815344674.Google Scholar
  15. 15.
    Gunawardena J. Biological systems theory. Science. 2010;328(5978):581–2. Scholar
  16. 16.
    Harvard Medical School. What is immunology? Boston, MA. 2015. Accessed 20 Nov 2015.
  17. 17.
    Affymetrix-eBioscience. Cytokines-Atlas. Headquarters San Diego, CA 92121.USA. 2015. Accessed 20 Nov 2015.
  18. 18.
    American Cancer Society (ACS). Cancer prevention and early detection facts and figures 2015–2016. Atlanta: American Cancer Society. p. 2015.Google Scholar
  19. 19.
    Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357(9270):1777–89. Scholar
  20. 20.
    Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature. 2007;449(7164):819–26. Scholar
  21. 21.
    Arazi A, Pendergraft WF III, Ribeiro RM, Perelson AS, Hacohen N. Human systems immunology: hypothesis-based modeling and unbiased data-driven approaches. Semin Immunol. 2013;25(3):193–200. Scholar
  22. 22.
    Stern PL, Einstein MH. Chapter 3 the immunobiology of human papillomavirus associated oncogenesis. In: Borruto F, De Ridder M, editors. HPV and cervical cancer: Springer Sicence+Business Media, LLC; 2012a. p. 45–61. Scholar
  23. 23.
    Stern PL, van der Burg SH, Hampson IN, Broker TR, Fiander A, Lacey CJ, et al. Therapy of human papillomavirus-related disease. Vaccine. 2012;30S(5):F71–82. Scholar
  24. 24.
    Timmis J, Knight T, de Castro LN, Hart E. An overview of artificial immune systems. In: Paton R, Bolouri H, Holcombe M, Tateson R, editors. Computation in cells and tissues, Natural Computing Series. Berlin, Heidelberg: Springer; 2004. ISBN: 978-3-642-05569-0.Google Scholar
  25. 25.
    Chu LH, Gangopadhyay A, Dorfleutner A, Stehlik C. An updated view on the structure and function of PYRIN domains. Apoptosis. 2015;20(2):157–73. Scholar
  26. 26.
    Illumina Technology. Immunology research review. An overview of recent immunology research. Publications Featuring Illumina®Technology. 2014. Accessed 30 Dec 2014.
  27. 27.
    Bourke CD, Prendergast CT, Sanin DE, Oulton TE, Hall RJ, Mountford AP. Epidermal keratinocytes initiate wound healing and pro-inflammatory immune responses following percutaneous schistosome infection. Int J Parasitol. 2015;45(4):215–24. Scholar
  28. 28.
    Bernard FX, Morel F, Camus M, Pedretti N, Barrault C, Garnier J, et al. Keratinocytes under fire of proinflammatory cytokines: bona fide innate immune cells involved in the physiopathology of chronic atopic dermatitis and psoriasis. J Allergy. 2012;718725:1–10. Scholar
  29. 29.
    Freedberg IM, Tomic-Canic M, Komine M, Blumenberg M. Keratins and the keratinocyte activation cycle. J Invest Dermatol. 2001;116(5):633–40. Scholar
  30. 30.
    Hoffmann GW. Immune network theory. 2nd ed. Burnaby, Canada: Printed by Still Creek Press; 2011. ISBN 978-0-9812196-0-8.Google Scholar
  31. 31.
    Markham JF, Wellard CJ, Hawkins ED, Duffy KR, Hodking PD. A minimum of two distinct heritable factors are required to explain correlation structures in proliferating lymphocytes. J R Soc Interface. 2010;7(48):1049–59. Scholar
  32. 32.
    Tarlinton D. B-cell differentiation: instructive one day, stochastic the next. Curr Biol. 2012;22(7):R235–7. Scholar
  33. 33.
    Kondo M. Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. Immunol Rev. 2010;238(1):37–46. Scholar
  34. 34.
    Tobón GJ, Izquierdo JH, Cañas CA. B lymphocytes: development, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus. Autoimmune Dis. 2013;2013(827254):1–17. Scholar
  35. 35.
    Ginhoux F, Jung S. Monocytes and macrophages developmental pathways and tissue homeostasis. Nat Rev Immunol. 2014;14(6):392–404. Scholar
  36. 36.
    Álvarez-Errico D, Vento-Torm R, Sieweke M, Ballestar E. Epigenetic control of myeloid cell differentiation, identity and function. Nat Rev Immunol. 2015;15(1):7–17. Scholar
  37. 37.
    Geissmann F, Manz MG, Jung S, Sieweke M, Merad M, Ley K. Development of monocytes, macrophages and dendritic cells. Science. 2010;327(5966):656–61. Scholar
  38. 38.
    Bortnick A, Allman D. What is what should always have been: long-lived plasma cells induced T-cell independent antigens. J Immunol. 2013;190(12):5913–8. Scholar
  39. 39.
    Kalia V, Sarkar S, Gourley TS, Rouse BT, Ahmed R. Differentiation of memory B and T cells. Curr Opin Immunol. 2006;18(3):255–64. Scholar
  40. 40.
    Nutt SL, Hodking PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160–71. Scholar
  41. 41.
    Wells A, Gudmundsdottir H, Turka LA. Following the fate of individual T cells throughout activation and clonal expansion. Signals from T cell receptor and CD28 differentially regulate the induction and duration of a proliferative response. J Clin Investig. 1997;100(12):3173–83. Scholar
  42. 42.
    Gudmundsdottir H, Wells AD, Turka LA. Dynamics and requirements of T cell clonal expansion in vivo at the single-cell level: effector function is linked to proliferativa capacity. J Immunol. 1999;162(9):5212–23.PubMedGoogle Scholar
  43. 43.
    Sebzda E, Mariathasan S, Ohteki T, Jones R, Bachmann MF, Ohashi PS. Selection of the T cell repertoire. Annu Rev Immunol. 1999;17:829–74. Scholar
  44. 44.
    Efroni S, Harel D, Cohen IR. Emergent dynamics of thymocyte development and lineage determination. PLoS Comput Biol. 2007;3(1):e13. Scholar
  45. 45.
    Fiúza UM, Arias AM. Cell and molecular biology of Notch. J Endocrinol. 2007;194(3):459–74. Scholar
  46. 46.
    Zabriskie J, editor. Essential clinical immunology. New York: The Rockefeller University, Cambridge University Press; 2009. ISBN-13 978-0-521-51681-5.Google Scholar
  47. 47.
    Henderson A, Calame K. Transcriptional regulation during B cell development. Annu Rev Immunol. 1998;16:163–200. Scholar
  48. 48.
    De Wit J, Jorritsma T, Makuch M, Remmerswall EBM, Bos HK, Souwer Y, et al. Human B cells promote T-cell plasticity to optimize antibody response by inducing coexpression of TH1/TFH signatures. J Allergy Clin Immunol. 2015;135(4):1053–60. Scholar
  49. 49.
    Bachmann MF, Zinkernagel RM. Neutralizing antiviral B cell responses. Annu Rev Immunol. 1997;15:235–70. Scholar
  50. 50.
    Mempel TR, Henrickson SE, von-Andrian UH. T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature. 2004;427(2970):154–9. Scholar
  51. 51.
    Zhu J, Mohan C. Toll-Like receptor signaling pathways-therapeutic opportunities. Mediat Inflamm. 2010;2010(781235):1–7. Scholar
  52. 52.
    DeCarlo CA, Rosa B, Jackson R, Niccoli S, Escott NG, Zehbe I. Toll-like receptor transcriptome in the HPV-positive cervical cancer microenvironment. Clin Dev Immunol. 2012;2012(785825):1–9. Scholar
  53. 53.
    Kanneganti T-D. Central roles of NLRs and inflammasomes in viral infection. Nat Rev Immunol. 2010;10(10):688–98. Scholar
  54. 54.
    So EY, Ouchi T. The application of Toll like receptors for cancer therapy. Int J Biol Sci. 2010;6(7):675–81. Scholar
  55. 55.
    Frazao JB, Errante PR, Condino-Neto A. Toll-like receptors’ pathway disturbances are associated with increased susceptibility to infections in humans. Arch Immunol Ther Exp. 2013;61(6):427–43. Scholar
  56. 56.
    Zhou Q, Zhu K, Cheng H. Toll-like receptors in human papillomavirus infection. Arch Immunol Ther Exp. 2013;61(3):203–15. Scholar
  57. 57.
    Jensen S, Thomsen AR. Sensing of RNA viruses: a review of innate immune receptors involved in recognizing RNA virus invasion. J Virol. 2012;86(6):2900–10. Scholar
  58. 58.
    Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The innate immune response to bacterial flagellin is mediated by toll-like receptor 5. Nature. 2001;410(6832):1099–103. Scholar
  59. 59.
    Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of Toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res. 2012;35(8):1297–316. Scholar
  60. 60.
    Ellerman JE, Brown CK, de Vera M, Zeh HJ, Billiar T, Rubartelli A, et al. Masquerader: high mobility group Box-1 and cancer. Clin Cancer Res. 2007;13(10):2836–48. Scholar
  61. 61.
    Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol. 2012;7(1):29–54. Scholar
  62. 62.
    Kim YK, Shin J-S, Nahm MH. Nod-like receptors in infection, immunity, and diseases. Yonsei Med J. 2016;57(1):5–14. Scholar
  63. 63.
    Eisenbarth SC, Williams A, Colegio OR, Meng H, Strowig T, Rongvaux A, et al. NLRP10 is a NOD-like receptor essential to initiate adaptive immunity by dendritic cells. Nature. 2012;484:510–3. Scholar
  64. 64.
    Motta V, Soares F, Sun T, Philpott DJ. Nod-like receptors: versatile cytosolic sentinels. Physiol Rev. 2015;95(1):149–78. Scholar
  65. 65.
    Man SM, Kanneganti T-D. Regulation of inflammasome activation. Immunol Rev. 2015;265(1):6–21. Scholar
  66. 66.
    Sun Q, Fan J, Billiar TR, Scott MJ. Inflammasome and autophagy regulation: a two-way street. Mol Med. 2017;23:188–95. Scholar
  67. 67.
    Anand PK, Malireddi RKS, Lukens JR, Vogel P, Bertin J, Lamkanfi M, et al. NLRP6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature. 2012 Aug;488:389–93. Scholar
  68. 68.
    Yan A, Farmer E, Wu TC, Hung CF. Perspectives for therapeutic HPV vaccine development. J Biomed Sci. 2016;23(1):75. Scholar
  69. 69.
    Morrone SR, Matyszewski M, Yu X, Delannoy M, Egelman EH, Son J. Assembly-driven activation of the AIM2 foreign-dsDNA sensor provides a polymerization template for downstream ASC. Nat Commun. 2015;6(7827):1–13. Scholar
  70. 70.
    Khare S, Ratsimandresy RA, de Almeida L, Cuda CM, Rellick SL, Misharin AB, et al. The pyrin domain-only protein POP3 inhibits ALR inflammasomes and regulates responses to infection with DNA viruses. Nat Immunol. 2014;15(4):343–53. Scholar
  71. 71.
    Reinholz M, Kawakami Y, Salzer S, Kreuter A, Dombrowski Y, Koglin S, et al. HPV16 activates the AIM2 inflammasome in keratinocytes. Arch Dermatol Res. 2013;305(8):723–32. Scholar
  72. 72. UniProt: a hub for protein information. Nucleic Acids Res. 43: D204-D212. 2015. Accessed 5 Jan 2015.
  73. 73.
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4(7):499–511. Scholar
  74. 74.
    O’Neill LAJ, Golenbock D, Bowie AG. The history of Toll-like receptors–redefining innate immunity. Nat Rev Immunol. 2013;13(6):453–60. Scholar
  75. 75.
    Lim KH, Staudt LM. Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 2013;5(1):a011247. Scholar
  76. 76.
    Amador-Molina A, Hernández-Valencia JF, Lamoyi E, Contreras-Paredes A, Lizano M. Rol of innate immunity against human papillomavirus (HPV) infections and effect of adjuvants in promoting specific immune response. Viruses. 2013;5(11):2624–42. Scholar
  77. 77.
    Daud II, Scott ME, Ma Y, Shiboski S, Farhat S, Moscicki AB. Association between toll-like receptor expression and human papillomavirus type 16 persistence. Int J Cancer. 2011;128(4):879–86. Scholar
  78. 78.
    Hasimu A, Ge L, Li QZ, Zhang RP, Guo X. Expressions of toll-like receptors 3, 4, 7, and 9 in cervical lesions and their correlation with HPV16 infection in Uighur women. Chin J Cancer. 2011;30(5):344–50. Scholar
  79. 79.
    Thompson MR, Kaminski JJ, Kirt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses. 2011 Jun;3(6):920–40. Scholar
  80. 80.
    Kanzler H, Barrat FJ, Hessel M, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonist and antagonist. Nat Med. 2007;13(5):552–9. Scholar
  81. 81.
    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373–84. Scholar
  82. 82.
    Bonjardim CA. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses- and viruses counteract IFN action. Microbes Infect. 2005;7(3):569–78. Scholar
  83. 83.
    Hennessy E, Parker AE, O’Neill LAJ. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9(4):293–307. Scholar
  84. 84.
    Yarovinsky F. Innate immunity to Toxoplasma gondii infection. Nat Rev Immunol. 2014;14(2):109–21. Scholar
  85. 85.
    Barton GM, Kagan JC. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol. 2009;9(8):535–42. Scholar
  86. 86.
    Morrison DK. MAP kinase pathways. Cold Spring Harb Perspect Biol. 2012;4:a011254. Scholar
  87. 87.
    Häcker H, Tseng PH, Karin M. Expanding TRAF function: TRAF3 as a tri-faced immune regulator. Nat Rev Immunol. 2011;11(7):457–68. Scholar
  88. 88.
    Hirsch I, Caux C, Hasan U, Bendriss-Vermare N, Olive D. Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol. 2010;31(10):391–7. Scholar
  89. 89.
    Lam LT, Wright G, Davis E, Lenz G, Farinha P, Dang L, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-kB pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008;111(7):3701–13. Scholar
  90. 90.
    Ngo V, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115–21. Scholar
  91. 91.
    American Cancer Society (ACS). Cancer immunotherapy. 2018. Accessed 28 May 2018.
  92. 92.
    Goazigo AR, Steenwinckel JV, Rostène W. Current status of chemokines in the adult CNS. Prog Neurobiol. 2013;104:67–92. Scholar
  93. 93.
    Hinck AP. Structural studies of the TGF-βs and their receptors – insights into evolution of the TGF-β superfamily. FEBS Lett. 2012;586(14):1860–70. Scholar
  94. 94.
    Lata S, Raghava GP. Prediction and classification of chemokines and their receptors. Protein Eng Des Sel. 2009;22(7):441–4. Scholar
  95. 95.
    Turner MD, Medjai B, Hurst T, Pennington DJ. Cytokines and chemokines: at the crossroads of cells signalling and inflammatory disease. Biochim Biophys Acta. 2014;1843(11):2563–82. Scholar
  96. 96.
    Shaikh PZ. Cytokines & their physiologic and pharmacologic functions in inflammation: a review. Int J Pharm Life Sci. 2011;2(11):1247–63.Google Scholar
  97. 97.
    Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H, Gomez E, et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. J Allergy Clin Immunol. 2011;127(3):701–721.e1-70. Scholar
  98. 98.
    Rosa MI, Morales MV, Vuolo F, Petronilho F, Bozzetti MC, Medeiors LR, et al. Association of interleukin-6 in women with persistence of DNA-HPV: a nested case-control study. Arch Gynecol Obstet. 2012;285(1):143–8. Scholar
  99. 99.
    Fernandes APM, Goncalves MAG, Duarte G, Cunha FQ, Simoes RT, Donadi EA. HPV16, HPV18, and HIV infection may be influence cervical cytokine intralesional levels. Virology. 2005;334(2):294–8. Scholar
  100. 100.
    Bohnhorst J, Rasmussen T, Moen SH, Flottum M, Knudsen L, Borset M, et al. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006;20(6):1138–44. Scholar
  101. 101.
    Jego G, Bataille R, Geffroy-Luseau A, Descamps G, Pellat-Deceunynck C. Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia. 2006;20(6):1130–7. Scholar
  102. 102.
    Lippitz B. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol. 2013;14(6):e218–28. Scholar
  103. 103.
    Padhan K, Varma R. Immunological synapse: a multi-protein signalling cellular apparatus for controlling gene expression. Immunology. 2010;129(3):322–8. Scholar
  104. 104.
    Li X, Jiang S, Tapping RI. Toll-like receptor in cell proliferation and survival. Cytokine. 2010;49(1):1–9. Scholar
  105. 105.
    Macian F. NFAT proteins: key regulators of T-cell development and function. Nat Rev Immunol. 2005;5(6):472–84. Scholar
  106. 106.
    Hu F, Meng Y, Gou L, Zhang X. Analysis of promoters and CREB/AP-1 binding sites of the human TMEM174 gene. Exp Ther Med. 2013;6(5):1290–4. Scholar
  107. 107.
    Wen AY, Sakamoto KM, Miller LS. The role of the transcription factor CREB in immune function. J Immunol. 2010;185(11):6413–9. Scholar
  108. 108.
    Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kB signalling pathways. Nat Immunol. 2011;12(8):695–708. Scholar
  109. 109.
    Hoesel B, Schmid JA. The complexity of NF-kB signaling in inflammation and cancer. Mol Cancer. 2013;12:86. Scholar
  110. 110.
    Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKgamma by SUMO-1 and ubiquitin mediates NF-kappaB activation by genotoxic stress. Cell. 2003;115(5):565–76. Scholar
  111. 111.
    Yuan H, Fu F, Zhuo J, Wang W, Nishitani J, An DS, et al. Human papillomavirus type 16 E6 and E7 oncoproteins upregulate c-IAP2 gene expression and confer resistance to apoptosis. Oncogene. 2005;24:5069–78. Scholar
  112. 112.
    Snow WM, Stoesz BM, Kelly DM, Albensi BC. Roles for NF-kB and gene targets of NF-kB in synaptic plasticity, memory, and navigation. Mol Neurobiol. 2014;49(2):757–70. Scholar
  113. 113.
    Micheau O, Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell. 2003;114(2):181–90. Scholar
  114. 114.
    Sen R. The origins of NF-kB. Nat Immunol. 2011;12:686–8. Scholar
  115. 115.
    Bassères DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006;25(51):6817–30. Scholar
  116. 116.
    Spitkovsky D, Hehner SP, Hofmann TG, Möller A, Schmitz ML. The human papillomavirus oncoprotein E7 attenuates NF-kB activation by targeting the IkB kinase complex. J Biol Chem. 2002;277(28):25576–82. Scholar
  117. 117.
    Pradeu T, Kostyrka G, Dupré J. Understanding viruses: philosophical investigation. Studies History Philo Biolog Biomed Sci. 2016;59:57–63. Scholar
  118. 118.
    Gibbs AJ, Gibbs MJ. A broader definition of ‘the virus species’ brief report. Arch Virol. 2006;151(7):1419–22. Scholar
  119. 119.
    International Committee on Taxonomy of Viruses (ICTV). ICTV Taxonomy. 2018. Accessed 29 Mar 2018.
  120. 120.
    Morgan GJ. What is a virus species? Radical pluralism in viral taxonomy. Stud Hist Phil Biol Biomed Sci. 2016;59:64–70. Scholar
  121. 121.
    Calisher CH. The taxonomy of viruses should include viruses. Arch Virol. 2016;161(5):1419–22. Scholar
  122. 122.
    McLaughlin-Drubin ME, Munger K. Viruses associated with human cancer. Biochim Biophys Acta. 2008;1782(3):127–50. Scholar
  123. 123.
    Ahuja R, Jamal A, Nosrati N, Pandley V, Rajput P, Saxena N, et al. Human oncogenic viruses and cancer. Curr Sci. 2014;107(5):768–85.Google Scholar
  124. 124.
    Santiago DN, Heidbuechel JPW, Kandell WM, Walker R, Djeu J, Engeland CE, et al. Fighting cancer with mathematics and viruses. Viruses. 2017;9(9):239. Scholar
  125. 125.
    Flippot R, Malouf GG, Su X, Khayat D, Spano J-P. Oncogenic viruses: lessons learned using next-generation sequencing technologies. Eur J Cancer. 2016;61:61–8. Scholar
  126. 126.
    Moore PS, Chang Y. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Nat Rev Cancer. 2010;10(12):878–89. Scholar
  127. 127.
    Nomaguchi M, Fujita M, Miyazaki Y, Adachi A. Viral Tropism. Front Microbiol. 2012;3:281. Scholar
  128. 128.
    Crow MS, Javitt A, Cristea LLM. A proteomics perspective on viral DNA sensors in host defense and viral immune evasion mechanisms. J Mol Biol. 2015;427(11):1995–2012. Scholar
  129. 129.
    Law GL, Korth MJ, Benecke AG, Katze MG. Systems virology: host-directed approaches to viral pathogenesis and drug targeting. Nat Rev Microbiol. 2013;11(7):455–66. Scholar
  130. 130.
    Schäfer G, Blumenthal MJ, Katz AA. Interaction of human tumor viruses with host cell surface receptors and cell entry. Viruses. 2015;7(5):2592–617. Scholar
  131. 131.
    Nowak MA, May RM. Viral dynamics: mathematical principles of immunology and viro-logy. Oxford, UK: Oxford University Press; 2001. p. 2–3. ISBN 0-19-850417-9.Google Scholar
  132. 132.
    Van Regenmortel MHV. The metaphor that viruses are living is alive and well, but it is no more than a metaphor. Stud Hist Phil Biol Biomed Sci. 2016;59:117–24. Scholar
  133. 133.
    Lin CZ, Xiang GL, Zhu XH, Xiu LL, Sun JX, Zhang XY. Advances in the mechanisms of action of cancer-targeting oncolytic viruses. Oncol Lett. 2018;15(4):4053–60. Scholar
  134. 134.
    Kuss-Duerkop SK, Westrich JA, Pyeon D. DNA tumor virus replication of host DNA methylation and its implications for immune evasion and oncogenesis. Viruses. 2018;10(2):E82. Scholar
  135. 135.
    Jiang M, Imperiale MJ. Design starts: how small DNA viruses remodel the host nucleus. Futur Virol. 2012;7(5):445–59. Scholar
  136. 136.
    Turnell AS, Grand RJ. DNA viruses and the cellular DNA-damage response. J Gen Virol. 2012;93(Pt 10):2076–97. Scholar
  137. 137.
    Saldivar JC, Cortez D, Cimprich KA. The essential kinase ATR: ensuring faithful duplication of a challenging genome. Nat Rev Mol Cell Biol. 2017;18(10):622–36. Scholar
  138. 138.
    Zhao J, Dang X, Zhang P, Nguyen LN, Cao D, Wang L, et al. Insufficiency of DNA repair enzyme ATM promotes naïve CD4 T-cell loss in chronic hepatitis C virus infection. Cell Discovery. 2018;4:16. Scholar
  139. 139.
    American Cancer Society (ACS). Cancer prevention and early detection facts and figures 2017–2017. Atlanta: American Cancer Society. 2017.Google Scholar
  140. 140.
    Seeger C, Mason WS. Molecular biology of hepatitis B virus infection. Virology. 2015;479–480:672–86. Scholar
  141. 141.
    Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163–86. Scholar
  142. 142.
    Xu W, Yu J, Wong VW-S. Mechanism and predictions of HCC development in HBV infection. Best Pract Res Clin Gastroenterol. 2017;31(3):291–8. Scholar
  143. 143.
    Levrero M, Zucman-Rossi J. Mechanism of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84–S101. Scholar
  144. 144.
    De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17–27. Scholar
  145. 145.
    Picconi MA, Alonio LV, García-Carrancá A, Lizano M, Cervantes-Vazquez G, Distefano AL, et al. Molecular variants of human papillomavirus (HPV) types 16 and 18 in adenocarcinomas of the cervix. Medicina (Buenos Aires). 2000;60(6):889–94.Google Scholar
  146. 146.
    Travasso CM, Anand M, Samarth M, Deshpande A, Kumar-Sinha C. Human papillomavirus genotyping by multiplex pyrosequencing in cervical cancer patients from India. J Biosci. 2008;33(1):73–80.PubMedGoogle Scholar
  147. 147.
    Cal CM. El virus del papiloma humano. Cadernos de Atención Primaria. 2008;15(1):72–4.Google Scholar
  148. 148.
    Goering RV. Molecular epidemiology of nosocomial infection: analysis of chromosomal restriction fragment patterns by pulsed-field gel electrophoresis. Infect Control Hosp Epidemiol. 1993;14(10):595–600.PubMedGoogle Scholar
  149. 149.
    Chan SY, Bernard HU, Ratterree M, Birkebak TA, Faras AJ, Ostrow RS. Genomic diversity and evolution of papillomaviruses in rhesus monkeys. J Virol. 1997;71(7):4938–43.PubMedPubMedCentralGoogle Scholar
  150. 150.
    Vanegas VA, Rubio AI, Bedoya AM, Sánchez GI. Estructura molecular y antigénica de la vacuna contra el virus de papiloma humano 16 (VPH 16). Acta Biológica Colombiana. 2008;13(3):37–48.Google Scholar
  151. 151.
    Yamada T, Wheeler CM, Halpern AL, Stewart AC, Hildesheim A, Jenison SA. Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol. 1995;69(12):7743–53.PubMedPubMedCentralGoogle Scholar
  152. 152.
    Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM. Human papillomavirus type 16 sequence variation in cervical cancer: a worldwide perspective. J Virol. 1997;71(3):2463–72.PubMedPubMedCentralGoogle Scholar
  153. 153.
    Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, et al. Human papillomavirus type 16 genetic variants: phylogeny and classification based on E6 and LCR. J Virol. 2012;86(12):6855–61. Scholar
  154. 154.
    Taylor ER, Morgan IM. A novel technique with enhanced detection and quantitation of HPV-16 E1- and E2-mediated DNA replication. Virology. 2003;315(1):103–9. Scholar
  155. 155.
    Okoye A, Cordano P, Taylor ER, Morgan IM, Everett R, Campo MS. Human papillomavirus 16 L2 inhibits the transcriptional activation function, but not the DNA replication function, of HPV-16 E2. Virus Res. 2005;108(1–2):1–14. Scholar
  156. 156.
    International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenesis risks to humans. vol. 100B. IARC Press 2012. ISBN 978 92 832 1319 2. ISSN 1017-1606. Lyon, France.Google Scholar
  157. 157.
    Flores ER, Allen-Hoffman BL, Lee D, Sattler CA, Lambert PF. Establishment of the human papillomavirus type 16 (HPV-16) life cycle in an immortalized human foreskin keratinocyte cell line. Virology. 1999;262(2):344–54. Scholar
  158. 158.
    Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol. 2004;4(1):46–55. Scholar
  159. 159.
    Polyomaviridae Study Group of the International on Taxonomy of viruses, Calvignac-Spencer S, Feltkamp MCW, Dauherty MD, Moens U, Ramqvist T, et al. A taxonomy update for the family polyomaviridae. Arch Virol. 2016;161(6):1739–50. Scholar
  160. 160.
    Liu W, MacDonald M, You J. Merkel cell polyomavirus infection and Merkel cell carcinoma. Curr Opin Virol. 2016;20:20–7. Scholar
  161. 161.
    Bhart H, Solis M, Kack-Kack W, Soulier E, Velay A, Fafi-Kremer S. In vitro and in vivo models for the study of human polyomavirus infection. Viruses. 2016;8(10):292. Scholar
  162. 162.
    Wendzicki JA, Moore PS, Chang Y. Large T and small T antigens of Merkel cell polyomavirus. Curr Opin Virol. 2015;11:38–43. Scholar
  163. 163.
    Spurgeon ME, Lambert PF. Merkel cell polyomavirus: a newly discovered human virus. Virology. 2013;435(1):118–30. Scholar
  164. 164.
    Cook DL, Frieling GW. Merkel cell carcinoma: a review and update on current concepts. Diagn Histopathol. 2016;22(4):127–33. Scholar
  165. 165.
    Van der Meijden E, Kazem S, Dargel CA, Vuren NV, Hensbergen PJ, MCW F. Characterization of T antigens, including middle T and alternative T, expressed by the human polyomavirus associated with trichodysplasia spinulosa. J Virol. 2015;89(18):9427–39. Scholar
  166. 166.
    Shuda M, Kwun HJ, Feng H, Chang Y, Moore P. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest. 2011;121(9):3623–34. Scholar
  167. 167.
    Esau D. Viral causes of lymphoma: the history of Epstein-Barr virus and human T-lymphotropic virus 1. Virology. 2017;8:1–5. Scholar
  168. 168.
    International Agency for Research on Cancer (IARC). Section of infections – infections and cancer biology group. 2018a. Accessed 27 Mar 2018.
  169. 169.
    Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319(5866):1096–100. Scholar
  170. 170.
    Kassem A, Schöpflin A, Diaz C, Weyers W, Stickeler E, Werner M, et al. Frequent detection of Merkel cell polyomavirus in human Merkel cell carcinomas and identification of a unique deletion in the VP1 gene. Cancer Res. 2008;68(13):5009–13. Scholar
  171. 171.
    Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al. T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci U S A. 2008;105(42):16272–7. Scholar
  172. 172.
    Moore PS, Chang Y. Common commensal cancer viruses. PLoS Pathog. 2017;13(1):e1006078. Scholar
  173. 173.
    Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocelular carcinoma; a systematic review. Hepatol Res. 2016;46(5):391–406. Scholar
  174. 174.
    Yue D, Zhang Y, Cheng L, Ma J, Xi Y, Yang L, et al. Hepatitis B virus X protein (HBx) induced abnormalities of nucleic acid metabolism revealed by H-NMR-based metabonomics. Sci Rep. 2016;6(24430):1–13. Scholar
  175. 175.
    World Health Organization (WHO). Weekly epidemiological record. 2014;43(89):465–92. ISSN 0049-8114.Google Scholar
  176. 176.
    Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 2007;121(1):1–14. Scholar
  177. 177.
    Yuzhalin A, Kutikhin A. Interleukins in cancer biology: their heterogeneous role. Chapter 1–10, edited by Arseniy E. Yuzhalin Anton G. Kutikhin, Academic Press, Amsterdam, 2015. ISBN 9780128011218.Google Scholar
  178. 178.
    Read SA, Douglas MW. Virus induced inflammation and cancer development. Cancer Lett. 2014;345(2):174–81. Scholar
  179. 179.
    Torres-Poveda K, Bahena-Román M, Madrid-González C, Burguete-García AI, Bermúdez-Morales VH, Peralta-Zaragoza O, et al. Role of IL-10 and TGF-β1 in local immunosuppression in HPV-associated cervical neoplasia. World J Clin Oncol. 2014;5(4):753–63. Scholar
  180. 180.
    Jeon S, Allen-Hoffmann BL, Lambert PF. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J Virol. 1995;69(5):2989–97.PubMedPubMedCentralGoogle Scholar
  181. 181.
    Zhou F, Leggatt GR, Frazer IH. Human papillomavirus 16 E7 protein inhibits interferon-γ-mediated enhancement of keratinocytes antigen processing and T-cell lysis. FEBS J. 2011;278(6):955–63. Scholar
  182. 182.
    Ren C, Cheng X, Lu B, Yang G. Activation of interleukin-6/signal transducer and activator of transcription 3 by human papillomavirus early proteins 6 induces fibroblast senescence to promote cervical tumourigenesis through autocrine and paracrine pathways in tumour microenvironment. Eur J Cancer. 2013;49(18):3889–99. Scholar
  183. 183.
    Song D, Li H, Li H, Dai J. Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer. Oncol Lett. 2015;10(2):600–6. Scholar
  184. 184.
    Aggarwal R, Misra S, Guleria C, Suri V, Mangat N, Sharma M, et al. Characterization of toll-like receptor transcriptome in squamous cell carcinoma of cervix: a case-control study. Gynecol Oncol. 2015;138(2):358–62. Scholar
  185. 185.
    Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol Rev. 2011;239(1):85–98. Scholar
  186. 186.
    Bermúdez-Morales VH, Peralta-Zaragoza O, Alcocer-González JM, Moreno J, Madrid-Marina V. IL-10 expression is regulated by HPV E2 protein in cervical cancer cells. Mol Med Rep. 2011;4(2):369–75. Scholar
  187. 187.
    Conesa-Zamora P. Immune responses against virus and tumor in cervical carcinogenesis: treatment strategies for avoiding the HPV-induced immune escape. Gynecol Oncol. 2013;131(2):480–8. Scholar
  188. 188.
    Song SH, Lee JK, Seok OS, Saw HS. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix. Gynecol Oncol. 2007;104(3):732–8. Scholar
  189. 189.
    Vandermark ER, Deluca KA, Gardner CR, Marker DF, Schreiner CN, Strickland DA, et al. Human papillomavirus type 16 E6 and E7 proteins alter NF-kB in cultured cervical epithelial cells and inhibition of NF-kB promotes cell growth and immortalization. Virology. 2012;425(1):53–60. Scholar
  190. 190.
    Houben R, Angermeyer S, Haferkamp S, Aue A, Goebeler M, Schrama D, et al. Characterization of functional domains in the Merkel cell polyoma virus large T antigen. Int J Cancer. 2015;136(5):E290–300. Scholar
  191. 191.
    Sauer CM, Haugg AM, Chteinberg E, Rennspiess D, Winnepenninckx V, Speel E-J, et al. Reviewing the current evidence supporting early B-cells as the cellular origin of Merkel cell carcinoma. Crit Rev Oncol Hematol. 2017;116:99–105. Scholar
  192. 192.
    Van der Meijden E, Feltkamp M. The human polyomavirus middle and alternative T-antigens: thoughts on roles and relevance to cancer. Front Microbiol. 2018;9:398. Scholar
  193. 193.
    Wang RF, Wang H. Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Res. 2017;27(1):11–37. Scholar
  194. 194.
    Obeid JM, Hu Y, Slingluff CL Jr. Vaccines, adjuvants and dendritic cell activators – current status and futures challenges. Semin Oncol. 2015;42(4):549–61. Scholar
  195. 195.
    Ophir E, Bobisse S, Coukos G, Harari A, Kandalaft LE. Personalized approaches to active immunotherapy in cancer. Biochim Biophys Acta. 2016;1865(1):72–82. Scholar
  196. 196.
    Song Q, Zhang C-D, Wu X-H. Therapeutic cancer vaccines: from initial findings to pros-pects. Immunol Lett. 2018;196:11–21. Scholar
  197. 197.
    Zamarin D, Postow MA. Immune checkpoint modulation: rationale design of combination strategies. Pharmacol Ther. 2015;150:23–32. Scholar
  198. 198.
    Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immuno-suppression. Expert Opin Biol Ther. 2010;10(7):1019–35. Scholar
  199. 199.
    Handisurya A, Lázár S, Papay P, Primas C, Haitel A, Horvat R, et al. Anogenital human papillomavirus prevalence is unaffected by therapeutic tumour necrosis factor-alpha inhibition. Acta Derm Venereol. 2016;96(4):494–8. Scholar
  200. 200.
    Werberich GM, Strava T, Vizioli C, Fernandes GDS. Human papillomavirus-induced cancer: late relapse in a patient treated with tumor necrosis factor-alpha inhibitor. J Global Oncol. 2016;3(3):275–7. Scholar
  201. 201.
    Neuzillet C, Tijeras-Raballand A, Cohen R, Cros J, Faivre S, Raymond E, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015;147:22–31. Scholar
  202. 202.
    Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 2003;424(6948):516–23. Scholar
  203. 203.
    DeCarlo CA, Severini A, Edler L, Escott NG, Lambert PF, Ulanova M, et al. IFN-κ, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes. Lab Investig. 2010;90(10):1482–91. Scholar
  204. 204.
    Cancer Research UK (CRUK). Other treatments. 2018. Accessed 30 May 2018.
  205. 205.
    Abdo J, Cornell DL, Mittal SK, Agrawal DK. Immunotherapy plus cryotherapy: potential augmented abscopal effect for advanced cancers. Front Oncol. 2018;8(85):1–16. Scholar
  206. 206.
    Russell SJ, Peng K-W, Bell JC. Oncolytyc virotherapy. Nat Biotechnol. 2012;30(7):658–70. Scholar
  207. 207.
    Chaurasiya S, Chen NG, Warner SG. Oncolytic virotherapy versus cancer stem cells: a review of approaches and mechanisms. Cancers. 2018;10(4):E124. Scholar
  208. 208.
    Liu Y, Sethi MS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, et al. Comparative molecular analysis of gastrointestinal adenocarcinomas. Cancer Cell. 2018;33(4):721–35. Scholar
  209. 209.
    Saleh T, Shojaosadati SA. Multifunctional nanoparticles for cancer immunotherapy. Hum Vaccin Immunother. 2016;12(7):1863–75. Scholar
  210. 210.
    Hu Z, Ott PA, Wu CJ. Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018;18(3):168–82. Scholar
  211. 211.
    Melief CJM, van Hall T, Arens R, Ossendorp F, van der Burg SH. Therapeutic cancer vaccines. J Clin Invest. 2015;125(9):3401–12. Scholar
  212. 212.
    Palucka K, Banchereau J. Dendritic cell-based cancer therapeutic vaccines. Immunity. 2013;39(1):38–48. Scholar
  213. 213.
    Sabado RL, Balan S, Bhardwaj N. Dendritic cell-based immunotherapy. Cell Res. 2017;27:74–95. Scholar
  214. 214.
    Shang N, Figini M, Shangguan J, Wang B, Sun C, Pan L, et al. Dendritic cells based immunotherapy. Am J Cancer Res. 2017;7(10):2091–102.PubMedPubMedCentralGoogle Scholar
  215. 215.
    Melief CJM. Cancer immunotherapy by dendritic cells. Immunity. 2008;29(3):372–83. Scholar
  216. 216.
    Kumai T, Kobayashi H, Harabuchi Y, Celis E. Peptide vaccines in cancer – old concept revisited. Curr Opin Immunol. 2017;45:1–7. Scholar
  217. 217.
    Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodisc for personalized cancer immunotherapy. Nat Mater. 2017;16(4):489–96. Scholar
  218. 218.
    Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY. Therapeutic cancer vaccines: past, present and future. Adv Cancer Res. 2013;119:421–75. Scholar
  219. 219.
    Li L, Pretrovsky N. Molecular mechanisms for enhanced DNA vaccine immunogenicity. Expert Rev Vaccines. 2016;15(3):313–29. Scholar
  220. 220.
    Yang B, Jeang J, Yang A, Wu TC, Hung CF. DNA vaccine for cancer immunotherapy. Hum Vaccin Immunother. 2014;10(11):3153–64. Scholar
  221. 221.
    Guo P, Wang J, Liu J, Xia M, Li W. Macrophage immigration inhibitory factor promotes cell proliferation and inhibits apoptosis of cervical adenocarcinoma. Tumour Biol. 2015;36(7):5095–102. Scholar
  222. 222.
    Sim GC, Radvanyi L. The IL-2 cytokine family in cancer immunotherapy. Cytokine Growth Factor Rev. 2014;25(4):377–90. Scholar
  223. 223.
    Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, et al. PD-1/PD-L1 blockade together with vaccine therapy facilitates effector T cell infiltration into pancreatic tumors. J Immunother. 2015;38(1):1–11. Scholar
  224. 224.
    Linch SN, Kasiewickz MJ, McNamara MJ, Hilgart-Martiszus IF, Farhad M, Redmond WL. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. Proc Natl Acad Sci U S A. 2016;113(3):E319–27. Scholar
  225. 225.
    Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119–27. Scholar
  226. 226.
    Dutta R, Mahato RI. Recent advances in hepatocellular carcinoma therapy. Pharmacol Ther. 2017;173:106–17. Scholar
  227. 227.
    Hochnadel I, Kossatz-Boehlert U, Jedicke N, Lenzen H, Manns MP, Yevsa T. Cancer vaccines and immunotherapeutic approaches in hepatobiliary and pancreatic. Hum Vaccin Immunother. 2017;13(12):2931–52. Scholar
  228. 228.
    Bann DV, Deschler DG, Goyal N. Novel immunotherapeutic approaches for head and neck squamous cell carcinoma. Cancers. 2016;8(10):E87. Scholar
  229. 229.
    Tello TL, Coggshall K, Yom SS, Yu SS. Merkel cell carcinoma: an update and review: current and future therapy. J Am Acad Dermatol. 2018;78(3):445–54. Scholar
  230. 230.
    Harms PW. Update on Merkel cell carcinoma. Clin Lab Med. 2017;37(3):485–501. Scholar
  231. 231.
    Delhalle S, Bode SFN, Balling E, Ollert M, He FQ. A roadmap towards personalized immunology. NPJ Syst Biol Appl. 2018;4(9):1–14. Scholar
  232. 232.
    Silva JM, Videira M, Gaspar R, Préat V, Florindo HF. Immune system targeting by biodegradable nanoparticles for cancer vaccines. J Control Release. 2013;168(2):179–99. Scholar
  233. 233.
    Sahin U, Türeci O. Personalized vaccines for cancer immunotherapy. Science. 2018;359(6382):1355–60. Scholar
  234. 234.
    Zhang X, Sharma PK, Goedegebuure P, Gillanders WE. Personalized cancer vaccines: targeting the cancer mutanome. Vaccine. 2017;35(7):1094–100. Scholar
  235. 235.
    Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17(4):209–22. Scholar
  236. 236.
    Gruijl TD, van den Eertwegh AJM, Pinedo HM, Scheper RJ. Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57(10):1569–77. Scholar
  237. 237.
    Bencherif SA, Sands RW, Ali OA, Li WA, Lewin SA, Braschler TM, et al. Injectable cryogel-based whole cell cancer vaccines. Nat Commun. 2015;6:7556. Scholar
  238. 238.
    Kandalaft LE, Chiang CL, Tanyi J, Motz G, Balint K, Mick R. A phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med. 2013;11:149. Scholar
  239. 239.
    Yang YW, Luo WH. Cellular biodistribution of polymeric nanoparticles in the immune system. J Control Release. 2016;227:82–93. Scholar
  240. 240.
    Bolhassani A, Javanzad S, Saleh T, Hashemi M, Aghasadeghi MR, Sadat SM. Polymeric nanoparticles: potent vector s for vaccine delivery targeting cancer and infectious diseases. Hum Vaccin Immunother. 2014;10(2):321–32. Scholar
  241. 241.
    Le Gall CM, Weiden J, Eggermont LJ, Figdor CG. Dendritic cells in cancer immunotherapy. Nat Mater. 2018;17:472–7. Scholar
  242. 242.
    Zhu M, Wang R, Nie G. Applications of nanomaterials as vaccine adjuvants. Hum Vaccin Immunother. 2014;10(9):2761–74. Scholar
  243. 243.
    Zhu G, Lynn GM, Jacobson O, Chen K, Liu Y, Zhang H, et al. Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017;8(1954):1–15. Scholar
  244. 244.
    Fecek RJ, Storkus WJ. Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. Immunotherapy. 2016;8(10):1205–18. Scholar
  245. 245.
    Koido S. Dendritic-tumor fusion cell-based cancer vaccines. Int J Mol Sci. 2016;17(6):E828. Scholar
  246. 246.
    Castiglione F, Bernaschi M. Epitope screening and cell cooperation in the immune response. Intelligent Systems, Modelling and Simulations (ISMS). Proceedings – 2011 2nd International Conference on Intelligence Systems, Modeling and Simulations. ISMS. 2011 Feb;127–132.
  247. 247.
    Daudi J. An overview of application of artificial immune system in swarm robotic systems. Adv Robotics Automat. 2015;4:127. Scholar
  248. 248.
    Zeeshan M, Javed H, Haider A, Khan A. An immunology inspired flow control attack detection using negative selection with r-contiguous bit matching for wireless sensor networks. Int J Distrib Sensor Networ 2015;11(11):1–7. doi: Scholar
  249. 249.
    Khan MT, de Silva, CW. Autonomous fault tolerance multi-robot cooperation using artificial immune system. Automation and Logistics. ICAL 2008. IEEE International Conference on 2008. 2008 Sep;623–8.
  250. 250.
    Nigam D, Kumar V. Artificial immune system: a potential tool to handle bioinformatics issues. Int J Artif Intell Knowl Discov. 2012;2(1):1–5.Google Scholar
  251. 251.
    Saybani MR, Shamshirband S, Hormozi SG, Wah TY, Aghabozorgi S, Pourhoseingholi MA, et al. Diagnosing tuberculosis with a novel support vector machine-based artificial immune system recognition system. Iran Red Crescent Med J. 2015;17(4):e24557. Scholar
  252. 252.
    Onomza WV, Alhassan J, Alelere M, Tunde A. Development of secure plus antivirus with the artificial immune system model. Int J Innov Technol Res. 2015;3(2):1882–96.Google Scholar
  253. 253.
    Rai N, Singh A. Improved clonal selection algorithm (ICLONALG). Int J Current Eng Technol. 2015;5(4):2459–64.Google Scholar
  254. 254.
    Ali NIM, Malek MA, Ismail AR. Immune network algorithm in monthly streamflow prediction at Johor river. ARPN J Eng Appl Sci. 2015;10(3):1352–6.Google Scholar
  255. 255.
    Zeng J. Computer malicious executables detection based on real-valued negative selection algorithm. Appl Math Inform Sci. 2015;9(2):1089–94. Scholar
  256. 256.
    Liò P, Miglino O, Nocosia G, Nolfi S, Pavone M. Advances in artificial life: synthesis and simulation of living systems: editorial. Artif Life. 2015;21(4):395–7. Scholar
  257. 257.
    Langton CG. Artificial Life: proceedings of an interdisciplinary workshop on the synthesis and simulation of living systems, held September, 1987, in Los Alamos, New Mexico, Santa Fe Institute Studies in the Sciences of Complexity. 1989; vol VI. Addison-Wesley.Google Scholar
  258. 258.
    Ray TS. An evolutionary approach to synthetic biology: zen and the art of creating life. Artif Life. 1994;1(1/2):195–226.. MIT Press. Scholar
  259. 259.
    Aguilar W, Santamaría-Bonfil G, Froese T, Gershenson C. The past, present, and future for artificial life. Front Robotics AI. 2014;1:8. Scholar
  260. 260.
    Williams RA. Lesson learned on development and application of agent-based models of complex dynamical systems. Simul Model Pract Theory. 2018;83:201–12. Scholar
  261. 261.
    Komosinski M, Adamatzky A, editors. Artificial life models in software. Second ed: Springer; 2009. Scholar
  262. 262.
    Bauer AL, Beauchemin CAA, Perelson AS. Agent-based modeling of host-pathogen systems: the successes and challenges. Inf Sci. 2009;179(10):1379–89. Scholar
  263. 263.
    Elkalaawy N, Wassal A. Methodologies for the modeling and simulation of biochemical networks, illustrated for signal transduction pathways: a primer. Biosystems. 2015;129:1–18. Scholar
  264. 264.
    Helbing D, Balietti S. How to do agent-based simulations in the future: from modeling social mechanism to emergent phenomena and interactive systems design. Chapter 2: agent-based modeling of the book Social Self-Organization. Springer, Berlin. 2012 Feb;25–70. 2.Google Scholar
  265. 265.
    An G, Mi Q, Dutta-Moscato J, Vodovotz Y. Agent-based models in translational systems biology. WIREs Syst Biol Med. 2009;1(2):159–71. Scholar
  266. 266.
    Hwang M, Garbey M, Berceli SA, Tran-Son-Tay R. Rule-based simulation of multi-cellular biological systems – a review of modeling techniques. Cell Mol Bioeng. 2009;2(3):285–94. Scholar
  267. 267.
    North MJ, Macal CM. Foundations of and recent advances in artificial life modeling with repast 3 and repast symphony. In: Komosinski M, Adamatzky A, editors. Artificial life models in software. London: Springer; 2009;. Chapter 2. p. 37–60.Google Scholar
  268. 268.
    Pezzulo G, Levin M. Top-down models in biology: explanation and control of complex living systems above the molecular level. J R Soc Interface. 2016;13(24):1–16. Scholar
  269. 269.
    Loscalzo J, Barabasi AL. Systems biology and future of medicine. Wiley Interdiscip Rev Syst Biol Med. 2011;3(6):619–27. Scholar
  270. 270.
    Seiden PE, Celada F. A model for simulating cognate recognition and response in the immune system. J Theor Biol. 1992;158(3):329–57. Scholar
  271. 271.
    Celada F, Seiden PE. Affinity maturation and hypermutation in a simulation of the humoral immune response. Eur J Immunol. 1996;26(6):1350–8. Scholar
  272. 272.
    Meier-Schellersheim M, Mack G. SIMMUNE, a tool for simulating and analyzing immune system behavior. Cornell University Library. 1999 Mar; arXiv:cs/9903017v1.
  273. 273.
    Bernaschi M, Castiglione F. Design and implementation of an immune system simulator. Comput Biol Med. 2001;31(5):303–31. Scholar
  274. 274.
    Puzone R, Kohler B, Seiden P, Celada F. IMMSIM, a flexible model for in machina expe-riments on immune system responses. Futur Gener Comput Syst. 2002;18(7):961–72. Scholar
  275. 275.
    Pappalardo F, Lollini PL, Castiglione F, Motta S. Modeling and simulation of cancer immunoprevention vaccine. Bioinformatics. 2005;21(12):2891–7. Scholar
  276. 276.
    Castiglione F, Bernaschi M, Succi S. Simulating the immune response on a distributed parallel computer. Int J Modern Phys C. 1997;8(3):527–45. Scholar
  277. 277.
    Bernaschi M, Castiglione F. Selection of escape mutants from immune recognition during HIV infection. Immunol Cell Biol. 2002 Jun;80(3):307–313.
  278. 278.
    Bandini S, Mauri G, Vizzari G. Supporting action-at-a-distance in situated cellular agents. Fundamenta Informaticae. 2006;69(3):251–71.Google Scholar
  279. 279.
    Baldazzi V, Castiglione F, Bernaschi M. An enhanced agent based model of the immune system response. Cell Immunol. 2006;244(2):77–9. Scholar
  280. 280.
    Castiglione F, Duca K, Jarrah A, Laubenbacher R, Hochberg D, Thorley-Lawson D. Simulating epstein–barr virus infection with C-ImmSim. Bioinformatics. 2007;23(11):1371–7. Scholar
  281. 281.
    Mata J, Cohn M. Cellular automata-based modeling program: synthetic immune system. Immunol Rev. 2007;216(1):198–212. Scholar
  282. 282.
    Maeda K, Sakama C. Identifying cellular automata rules. J Cell Autom. 2007;2(1):1–20.Google Scholar
  283. 283.
    Folcik VA, An GC, Orosz CG. The basic immune simulator: an agent-based model to study the interactions between innate and adaptive immunity. Theor Biol Med Model. 2007;4(39):1–18. Scholar
  284. 284.
    Dréau D, Dimitre S, Ted C, Mirsad H. An gent-based model of solid tumor progression. In: Rajasekaran S, editor. Bioinformatics and Computational Biology. BiCoB 2009. Lecture Notes in Computer Science. 2009;5462. Springer, Berlin, Heidelberg. doi: Scholar
  285. 285.
    De Pillis LG, Mallet DG, Radunskaya AE. Spatial tumor-immune modeling. Comput Math Methods Med. 2006;7(2–3):159–76. Scholar
  286. 286.
    Sneddon M, Faeder JR, Emonet T. Efficient modeling, simulation and coarse-graining of biological complexity with NFsim. Nat Methods. 2011;8(2):177–83. Scholar
  287. 287.
    Wendelsdorf KV, Alam M, Bassaganya-Riera J, Bisset K, Eubank S, Hontecillas R, et al. Enteric immunity simulator: a tool for in silico study of gastroenteric infections. IEEE Trans Nanobioscience. 2012;11(3):273–88. Scholar
  288. 288.
    Barret CL, Bisset KR, Eubank SG, Feng X, Marathe MV. Episimdemics: an efficient algorithm for simulating the spread of infectious disease over large realistic social networks. In: SC’2008: Proceedings of the 2008 ACM/IEEE Conference on Supercomputing. 2008 Nov;1–12.
  289. 289.
    Kim PS, Lee PP. Modeling protective anti-tumor immunity via preventative cancer vaccines using a hybrid agent-based and delay differential equation approach. PLoS Comput Biol. 2012;8(10):e1002742. Scholar
  290. 290.
    Mallet DG, De Pillis LG. A cellular automata model of tumor-immune system interactions. J Theor Biol. 2006;239(3):334–50. Scholar
  291. 291.
    Pappalardo F, Forero IM, Pennisi M, Palazon A, Melero I, Motta S. SimB16: modeling induced immune system response against B16-melanoma. PLoS One. 2011;6(10):e26523. Scholar
  292. 292.
    Von Eichborn J, Woelke AL, Castiglione F, Preissner R. VaccImm: simulating peptide vaccination in cancer therapy. BioMed Central Bioinform. 2013;14(127):1–8. Scholar
  293. 293.
    Santos J, Monteagudo A. Analysis of behavior transitions in tumour growth using a cellular automaton simulation. IET Syst Biol. 2015;9(3):75–87. Scholar
  294. 294.
    Shahmoradi S, Rahatabad FN, Maghooli K. A stochastic cellular automata model of growth of avascular tumor with immune response and immunotherapy. Inform Med Unlocked. 2018; Scholar
  295. 295.
    Boondireck A, Lenbury Y, Wong-Ekkabut J, Triampo W, Tang IM, Picha P. A stochastic model of cancer growth with immune response. J Korean Phys Soc. 2006;49(4):1652–66.Google Scholar
  296. 296.
    Bezzi M, Celada F, Ruffo S, Seiden PE. The transition between immune and disease states in a cellular automaton model of clonal immune response. Phys A Stat Mech Its Appl. 1997;245(1–2):145–63. Scholar
  297. 297.
    Celada F, Seiden P. Modeling immune cognition. IEEE International Conference on Systems, Man, and Cybernetics. San Diego, CA, USA. 1998 Oct; vol. 4, p. 3787–3792.
  298. 298.
    Kleinstein SH, Seiden PE. Simulating the immune system. Comput Sci Eng. 2000;2(4):69–77. Scholar
  299. 299.
    Kohler B, Puzone R, Seiden PE, Celada F. A systematic approach to vaccine complexity using an automaton model of the cellular and humoral immune system. I. Viral characteristics and polarized responses. Vaccine. 2000;19(7–8):862–76. Scholar
  300. 300.
    Stewart JJ, Agosto H, Litwin S, Welsh JD, Shlomchik M, Weigert M, Seiden PE. A solution to the rheumatoid factor paradox: pathologic rheumatoid factors can be tolerized by competition with natural rheumatoid factors. J Immunol. 1997;159(4):1728–38.PubMedGoogle Scholar
  301. 301.
    Bardi JS. New NIAID program aims to model immune responses and key infectious diseases. NIH/National Institute of Allergy and Infectious Diseases 2012 Jul. Accessed 8 Sep 2012.
  302. 302.
    Langman RE, Mata J, Cohn M. A computerized model for the self-non-self discrimination at the level of the Th (Th genesis). II. The behavior of the system upon encounter with non-self antigens. Int Immunol. 2003;15(5):593–609. Scholar
  303. 303.
    Emerson A, Rossi E. ImmunoGrid – the virtual human immune system project. Stud Health Technol Inform. 2007;126:87–92.PubMedGoogle Scholar
  304. 304.
    Halling-Brown M, Pappalardo F, Rapin N, Zhang P, Alemani D, Emerson A, et al. ImmunoGrid: towards agent-based simulations of the human immune system at a natural scale. Phil Trans R Soc A. 2010;368:2799–815. Scholar
  305. 305.
    Strain MC, Richman DD, Wong JK, Levine H. Spatiotemporal dynamics of HIV propagation. J Theor Biol. 2002;218(1):85–96. Scholar
  306. 306.
    Segovia-Juarez JL. Ganguli S, Kirschner D. identifying control mechanisms of granuloma formation during M. tuberculosis infection using an agent-based model. J Theor Biol. 2004;231(3):357–76. Scholar
  307. 307.
    Beauchemin C. MASyV: A Multi-Agent System Visualization program. Free open-source GNU GPL software available online on Accessed 9 Sep 2012.
  308. 308.
    Motta S, Castiglione F, Lollini P, Pappalardo F. Modelling vaccination schedules for a cancer immunoprevention vaccine. Immunome Res. 2005;1(5):1–18. Scholar
  309. 309.
    Alarcon T, Byrne HM, Maini PK. A multiple scale model for tumor growth. Society for Industrial and Applied Mathematics. Multiscale Model Simul. 2005;3(2):440–75. Scholar
  310. 310.
    Zhang Y, Wallace DL, de Lara CM, Ghattas H, Asquith B, Worth A, et al. In vivo kinetics of human natural killer cells: the effects of ageing and acute and chronic viral infection. Immunology. 2007;121(2):258–65. Scholar
  311. 311.
    Warrender C, Forrest S, Koster F. Modeling intercellular interactions in early Mycobaterium infection. Bull Math Biol. 2006;68(8):2233–61. Scholar
  312. 312.
    Shapiro M, Duca KA, Lee K, Delgado-Eckert E, Hawkins J, Jarrah AS, et al. A virtual look at Epstein–Barr virus infection: simulation mechanism. J Theor Biol. 2008;252(4):633–48. Scholar
  313. 313.
    Beauchemin C, Forrest S, Koster FT. Modeling influenza viral dynamics in tissue. In: Bersini H, Carneiro J, editors. Artificial immune systems. ICARIS 2006. Lecture notes in computer science, vol. 4163. Berlin: Springer; 2006. p. 23–36. Scholar
  314. 314.
    Ebeling W, Schweitzer F. Swarms of particle agents with harmonic interactions. Theory Biosci. 2001;120(3–4):207–24. Scholar
  315. 315.
    Macal CM, North MJ. Tutorial on agent-based modeling and simulation part 2: how to model with agents. Simulation Conference 2006, WSC 06. Proceedings of the 38th conference on winter simulation. IEEE. 2006 Dec; pp.73–83. ISBN:1–4244–0501-7.Google Scholar
  316. 316.
    Baird L, Fagin B. Conserved energy functions for cellular automata: finding nontrivials faster through a complete theory of the trivials. J Cell Autom. 2012;7(2):115–50.Google Scholar
  317. 317.
    Escobar-Ospina ME, Gómez-Perdomo J. A growth model of human papillomavirus type 16 designed from cellular automata and agent-based models. Artif Intell Med. 2013;57(1):31–47. Scholar
  318. 318.
    De Silva N, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol. 2015;15(3):137–48. Scholar
  319. 319.
    Hwang JK, Alt FW, Yeap LS. Related mechanisms of antibody somatic hypermutation and class switch recombination. Microbiol Spectr. 2015;3(1):MDNA3-0037-2014. Scholar
  320. 320.
    Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol. 2015;15(3):149–59. Scholar
  321. 321.
    Sen B, Johnson FM. Regulation of Src family kinases in human cancers. J Signal Transduc. 2011;865819:1–14. Scholar
  322. 322.
    Railsback SF, Lytinen SL, Jackson SK. Agent-based simulation platforms: review and development recommendations. SIMULATION. 2006;82(9):609–23. Scholar
  323. 323.
    Abar S, Theodoropoulos GK, Lemarinier P, O’Hare GMP. Agent based modelling and simulation tools: a review of the state-of-art software. Comput Sci Rev. 2017;24:13–33. Scholar
  324. 324.
    Hu C, Mao X, Li M, Zhu Z. Organization-based agent-oriented programming: model, mechanisms, and language. Front Comp Sci. 2014;8(1):33–51. Scholar
  325. 325.
    Ackley DH, Ackley ES. The ulam programming language for artificial life. Artif Life. 2016;22(4):431–50. Scholar
  326. 326.
    Yan Q, Li M, Liu Q, Li F, Zhu B, Wang J, et al. Molecular characterization of woodchuck IFI16 and AIM2 and their expression in woodchucks infected with woodchuck hepatitis virus (WHV). Sci Rep. 2016;6(28776):1–11. Scholar
  327. 327.
    Yi Z, Lin WW, Stunz LL, Bishop GA. Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions. Cytokine Growth Factor Rev. 2014;25(2):147–56. Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Engineering – Systems and ComputingUniversidad NacionalBogotáColombia

Personalised recommendations